AvantGen
A privately-held antibody discovery and optimization service provider utilizing yeast display technology for antibody discovery and optimization.
The USA-based company’s platform includes a yeast display system, large natural human antibody database, fully human antibody libraries comprised of more than 100 billion antibody clones, flow cytometry-based and other screening technologies, as well as novel methodologies for rabbit monoclonal antibody generation.
AvantGen’s partners include pharmaceutical, biotech, diagnostic and government entities.
Latest AvantGen News & Features
29 June 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze